Cariprazine – Mechanism of Action | Psychopharmacology | Clinical Application

Posted on:April 11, 2021
Last Updated: September 24, 2021
Time to read: 11–13 minutes

DRUG DESCRIPTION AND STRUCTURE

Cariprazine (Vraylar, Reagila) is an atypical antipsychotic approved in September 2015 to treat schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy. [McCormack 2015]

Cariprazine, or N-alkylpiperazine, is an organic compound consisting of a phenyl group bound to a piperazine skeleton. [Citrome 2013]

References